Researchers at the NYU Grossman School of Medicine in New York City analyzed patient records for 7,348 adults COVID-19 patients treated at NYU Langone Health between March 3 and May 21, 2020. Fourteen percent of patients were diagnosed with schizophrenia, mood disorders or anxiety.
Researchers found people with schizophrenia had a 2.7 times higher chance of dying, representing the second-largest risk factor behind age. People ages 75 and older had a 35.7 times higher risk of death. Patients with mood or anxiety disorders did not have a higher death risk, researchers said.
“Our findings illustrate that people with schizophrenia are extremely vulnerable to the effects of COVID-19,” lead author Katlyn Nemani, MD, a research assistant professor in the psychiatry department at NYU Langone Health, said in a news release. “With this newfound understanding, healthcare providers can better prioritize vaccine distribution, testing and medical care for this group.”
More articles on patient safety and outcomes:
Busy ICU linked to increase in COVID-19 deaths, study finds
76% of hospitalized COVID-19 patients have symptoms for 6 months, study finds
CMS limits on-site complaint, recertification surveys
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
